Fertility and sterility · 2009
Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.
Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lindsay Robert, Gallagher J Christopher, Kagan Risa, Pickar James H, Constantine Ginger
Аннотация
OBJECTIVE: To evaluate the efficacy of the tissue-selective estrogen complex, bazedoxifene/conjugated estrogens (BZA/CE), for postmenopausal osteoporosis prevention.
DESIGN: Multicenter, randomized, double-blind, placebo- and active-controlled, phase 3 trial (Selective estrogen Menopause And Response to Therapy [SMART]-1).
SETTING: Outpatient clinical study.
PATIENT(S): Women (n = 3,397) more than 5 years and 1-5 years postmenopause were enrolled in the Osteoporosis Prevention I and II Substudies, respectively.
INTERVENTION(S): Single tablets of BZA (10, 20, or 40 mg) each with CE (0.625 or 0.45 mg), raloxifene (60 mg), or a placebo taken daily for 2 years.
MAIN OUTCOME MEASURE(S): The primary outcome for both substudies was change in bone mineral density of the lumbar spine; bone mineral density was also measured at the hip.
RESULT(S): In both substudies, bone mineral density increased significantly more with all BZA/CE doses compared with placebo at the lumbar spine and total hip, and for most BZA/CE doses compared with raloxifene at the lumbar spine. Osteocalcin and N-telopeptide significantly decreased with all BZA/CE doses vs. placebo and most BZA/CE doses vs. raloxifene.
CONCLUSION(S): BZA/CE combinations decreased bone turnover and bone loss in postmenopausal women at increased risk for osteoporosis.
DESIGN: Multicenter, randomized, double-blind, placebo- and active-controlled, phase 3 trial (Selective estrogen Menopause And Response to Therapy [SMART]-1).
SETTING: Outpatient clinical study.
PATIENT(S): Women (n = 3,397) more than 5 years and 1-5 years postmenopause were enrolled in the Osteoporosis Prevention I and II Substudies, respectively.
INTERVENTION(S): Single tablets of BZA (10, 20, or 40 mg) each with CE (0.625 or 0.45 mg), raloxifene (60 mg), or a placebo taken daily for 2 years.
MAIN OUTCOME MEASURE(S): The primary outcome for both substudies was change in bone mineral density of the lumbar spine; bone mineral density was also measured at the hip.
RESULT(S): In both substudies, bone mineral density increased significantly more with all BZA/CE doses compared with placebo at the lumbar spine and total hip, and for most BZA/CE doses compared with raloxifene at the lumbar spine. Osteocalcin and N-telopeptide significantly decreased with all BZA/CE doses vs. placebo and most BZA/CE doses vs. raloxifene.
CONCLUSION(S): BZA/CE combinations decreased bone turnover and bone loss in postmenopausal women at increased risk for osteoporosis.
Предметные рубрики MeSH
Absorptiometry, PhotonAdultAgedBone DensityCollagen Type IDose-Response Relationship, DrugDouble-Blind MethodEstrogensEstrogens, Conjugated (USP)FemaleHip JointHumansIndolesLumbar VertebraeMiddle AgedOsteocalcinOsteoporosis, PostmenopausalPeptidesRaloxifene HydrochlorideRisk FactorsSelective Estrogen Receptor ModulatorsTreatment Outcome